Semaglutide vs Tirzepatide: Complete Comparison (2026)

In the only head-to-head clinical trial comparing the two (SURMOUNT-5), tirzepatide (Zepbound®) produced significantly more weight loss than semaglutide (Wegovy®) — 20.2% vs 13.7% average body-weight loss over 72 weeks at each drug's highest tolerated dose — with broadly similar tolerability. So for weight loss on average, tirzepatide is the more effective medication. That doesn't automatically make it the right choice: semaglutide has a longer post-market safety record, an FDA-approved cardiovascular risk-reduction indication, a daily-pill option, and a lower cost.

Both are injected once a week. Both reduce appetite. Both have been studied in tens of thousands of patients. Here's what the clinical evidence actually shows, side by side.

Quick comparison

How they work

Both medications mimic natural gut hormones that are released after eating — but tirzepatide mimics two of them, which is why it's often more effective.

Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist. When you eat, your gut releases GLP-1, which signals fullness to your brain, slows stomach emptying so food stays in your stomach longer, and prompts the pancreas to release insulin. Semaglutide mimics GLP-1 but lasts much longer in the body than the natural hormone — a single weekly injection maintains steady levels.

Tirzepatide is a dual agonist. It activates the same GLP-1 receptor as semaglutide, plus a second receptor called GIP (glucose-dependent insulinotropic polypeptide). GIP is another gut hormone that plays a role in fat metabolism and energy balance. By hitting both receptors, tirzepatide produces stronger appetite suppression and greater weight loss than GLP-1 alone.

If you want a deeper look at the receptor biology behind both — what GLP-1 actually does in your gut and brain, why GIP matters, and where the science is heading next — read our explainer on how GLP-1 and GIP work.

Effectiveness: what clinical trials actually showed

The headline numbers come from each drug's pivotal FDA trial — STEP 1 for semaglutide (marketed as Wegovy®) and SURMOUNT-1 for tirzepatide (marketed as Zepbound®). Both enrolled adults with obesity, or overweight plus a weight-related condition, paired the medication with lifestyle counseling, and ran about 68–72 weeks.

STEP 1 — semaglutide 2.4 mg weekly (Wegovy®):

• Average weight loss: 14.9% of body weight
• 50% of participants lost at least 15%
• 32% of participants lost at least 20%

SURMOUNT-1 — tirzepatide 15 mg weekly (Zepbound®):

• Average weight loss: 20.9% of body weight
• 57% of participants lost at least 20%

One caveat clinicians always raise: STEP 1 and SURMOUNT-1 were separate studies with different participants, so lining up their numbers side by side isn't a true apples-to-apples test. For that you need a head-to-head trial — and as of 2025, there is one.

The head-to-head trial: SURMOUNT-5

SURMOUNT-5 was the first large randomized trial to compare the two medications directly — same study, same time period, each at its highest tolerated dose — in adults with obesity (without diabetes), over 72 weeks.

• Tirzepatide (Zepbound®), 10 mg or 15 mg weekly: 20.2% average weight loss
• Semaglutide (Wegovy®), 1.7 mg or 2.4 mg weekly: 13.7% average weight loss

Tirzepatide produced significantly more weight loss — roughly 47% greater relative weight loss than semaglutide — and more participants reached every weight-loss threshold the study measured. Tolerability was broadly similar between the two, with the same gastrointestinal side-effect profile.

That makes SURMOUNT-5 the strongest single piece of evidence on this exact question: head-to-head, for weight loss, tirzepatide outperformed semaglutide. It does not mean tirzepatide is the right choice for everyone — cost, tolerability, individual response, and the non-weight benefits below all still matter, and many people reach their goals on semaglutide.

For a 220-lb starting weight, the trial averages translate to roughly 30 lbs on semaglutide vs 44 lbs on tirzepatide at the highest doses. The weight loss projection calculator will model your specific starting point against either curve.

These results are from the FDA-approved branded products (Wegovy® and Zepbound®) at the doses studied. Clinical trial outcomes for the FDA-approved products have not been established for compounded preparations. Individual results vary.

Wegovy® offers more options

The pivotal and head-to-head trial data above for Wegovy® (semaglutide) reflects its original injectable form and dosage, as approved for weight loss in 2021 — but that isn't the full picture. Two additional options have since been approved:

• Wegovy® pill: In the OASIS 4 trial, this once-daily 25 mg oral tablet produced an average weight loss of 13.6% after 64 weeks.
• Wegovy HD®: In the STEP UP trial, the 7.2 mg weekly injection produced an average weight loss of 18.7% after 72 weeks — compared with 15.6% for the 2.4 mg weekly injection over the same period.

Tirzepatide, by contrast, is only approved as a weekly injection. Some people prefer a weekly injection if they'd rather not keep track of a daily pill; others prefer having an oral option.

Dosing and titration

Both medications must be started at a low dose and increased gradually to minimize side effects — mostly nausea. Titrating too fast is the most common reason people quit GLP-1 therapy in the first month. Below are common examples of the dosing schedule for either injection.

Semaglutide titration (Wegovy®):

1. Weeks 1–4: 0.25 mg
2. Weeks 5–8: 0.5 mg
3. Weeks 9–12: 1.0 mg
4. Weeks 13–16: 1.7 mg
5. Week 17+: 2.4 mg (maintenance)

Tirzepatide titration (Zepbound®):

1. Weeks 1–4: 2.5 mg
2. Weeks 5–8: 5 mg
3. Weeks 9–12: 7.5 mg
4. Weeks 13–16: 10 mg
5. Weeks 17–20: 12.5 mg
6. Week 21+: 15 mg (maintenance)

Some patients reach their goal weight at a lower dose and never need to reach the maximum. Your provider adjusts titration based on how you're tolerating each step.

Side effects compared

The side effect profiles are very similar — both medications share the same core mechanism. The difference is mostly a matter of intensity, since tirzepatide produces greater weight loss (and greater GI effects scale with weight loss). Reassuringly, in the SURMOUNT-5 head-to-head trial the two drugs had broadly similar tolerability despite tirzepatide's larger weight loss.

Most common (both medications, affecting 20–40% of users in trials):

• Nausea (typically 1–4 weeks after each dose increase)
• Constipation
• Diarrhea
• Vomiting
• Abdominal discomfort

Less common but worth knowing:

• Fatigue (first few weeks)
• Loss of appetite to the point of under-eating (monitor protein intake)
• Injection site reactions (minor redness)
• Gallbladder issues (~1–3% of users; risk is higher with rapid weight loss)
• Abnormal skin sensations (dysesthesia; risk generally increases with higher doses)

Rare but serious:

• Pancreatitis
• Severe allergic reactions
• Risk of stomach contents getting into the lungs (aspiration) during surgery or procedures requiring general anesthesia
• Boxed warning: Due to the potential risk of thyroid C-cell tumors, both medications are contraindicated in people with a history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (based on animal studies; not conclusively linked in humans)

Most GI side effects resolve within 4–8 weeks after starting the medication or after each titration step. For a deeper look, read our complete guide to GLP-1 side effects.

Beyond weight loss: other proven benefits

Weight loss is the headline, but the two molecules have diverged in what else they've been shown to do — and for some patients these differences matter more than the weight-loss gap.

Semaglutide has the deeper cardiovascular dataset. In the SELECT trial, semaglutide 2.4 mg (Wegovy®) reduced the risk of major adverse cardiovascular events — heart attack, stroke, and cardiovascular death — in adults with established cardiovascular disease and overweight or obesity who did not have diabetes. On the strength of that trial, Wegovy® carries an FDA-approved indication to reduce that risk. Semaglutide (as Ozempic®) also has FDA-approved cardiovascular and kidney indications in type 2 diabetes. Additionally, Wegovy® is FDA-approved to treat a serious form of fatty liver disease known as metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate-to-advanced fibrosis.

Tirzepatide has a fast-growing body of evidence of its own. Zepbound® is FDA-approved to treat moderate-to-severe obstructive sleep apnea in adults with obesity — the first medication ever approved for that use — and tirzepatide has shown benefit in heart failure with preserved ejection fraction (the SUMMIT trial). Its dedicated cardiovascular-outcomes trial is still underway, so it does not yet carry a cardiovascular risk-reduction indication.

The practical takeaway: if you have established heart disease or MASH, semaglutide's indications may tip the balance; if obstructive sleep apnea is part of your picture, tirzepatide's approval is uniquely relevant. Your provider weighs these alongside the weight-loss data.

Cost comparison

This is usually the deciding factor for anyone paying out of pocket.

Brand-name pricing (without insurance)

With insurance coverage, these can drop to $25–150/month, but coverage for weight loss (non-diabetic indication) is inconsistent. Most commercial plans still don't cover weight-loss GLP-1s, and Medicare is prohibited by law from covering anti-obesity medications. Brand-name GLP-1s dispensed through Pallas are cash-pay only and are not billed to insurance.

Compounded pricing

Compounded preparations of semaglutide and tirzepatide — prepared by US-licensed compounding pharmacies on a per-patient basis when a licensed provider determines they are clinically indicated — cost dramatically less than brand-name products. At Pallas, compounded semaglutide injection is $139 for your first month, then $597 every 12 weeks ($199/mo average). Cancel anytime. Compounded tirzepatide injection is $179 for your first month, then $897 every 12 weeks ($299/mo average). Cancel anytime. Compounded oral semaglutide is $299/mo. Every plan includes your provider visits, dose adjustments, care-team messaging, and free shipping — there's no separate membership fee.

Which one should you choose?

There's no universally right answer — but there are patterns.

Tirzepatide tends to be better if:

• You have a significant amount of weight to lose (40+ lbs)
• Semaglutide hasn't worked well for you in the past
• Cost is not the primary constraint

Semaglutide tends to be better if:

• Your goal is more moderate (20–30 lbs)
• You want the medication with the longest post-market safety data
• You prefer a daily pill option

Either works if:

• Budget drives the decision (compounded versions of both cost far less than the brand-name products at Pallas)
• Your doctor recommends it based on your health history

Where the class is heading (and why it matters today)

You may have seen recent headlines about next-generation weight-loss drugs producing even greater results than tirzepatide in clinical trials. Here's the honest read on what that means for someone making a decision in 2026.

The current direction in obesity medicine is straightforward: each generation of drug activates more receptors and produces more weight loss. Semaglutide hits one receptor (GLP-1). Tirzepatide hits two (GLP-1 + GIP). Investigational compounds currently in Phase 3 trials add a third — the glucagon receptor — and early data has shown substantial weight-loss effects that exceed tirzepatide's SURMOUNT-1 numbers.

A few caveats worth being clear about:

• None of these triple-receptor compounds are FDA-approved as of May 2026. They are investigational, available only through clinical trials, and several are still being evaluated for long-term safety.
• Approval timelines are typically multi-year. Even if Phase 3 trials succeed, an FDA-approved next-generation drug is likely years away from a pharmacy shelf.
• Adding receptors adds complexity, not just effectiveness. Glucagon activation has metabolic effects on heart rate, lean mass, and the liver that researchers are still characterizing.
• For now, semaglutide and tirzepatide are the highest-evidence options patients can actually start today. Both have years of post-market safety data and extensive published trial results.

The practical implication: it's reasonable to follow the research, but it's not reasonable to wait for it. Patients who would benefit from starting today have two excellent FDA-approved options with established track records, and either one can be switched or layered into a longer-term plan if better medications eventually reach the market.

References

The trial figures and FDA approvals cited above come from the following primary sources. All efficacy data reflect the FDA-approved branded products at the doses studied.

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989–1002.
2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–216.
3. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. 2025;393(1):26–36.
4. Wharton S, Lingvay I, Bogdanski P, et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity (OASIS 4). N Engl J Med. 2025;393(11):1077–1087.
5. Wharton S, Freitas P, Hjelmesæth J, et al. Once-Weekly Semaglutide 7.2 mg in Adults with Obesity (STEP UP). Lancet Diabetes Endocrinol. 2025.
6. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389(24):2221–2232.
7. Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA). N Engl J Med. 2024;391(13):1193–1205.
8. Packer M, Zile MR, Kramer CM, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT). N Engl J Med. 2025;392(5):427–437.
9. U.S. Food and Drug Administration. FDA Approves Treatment for Serious Liver Disease Known as MASH. 2024.
10. U.S. Food and Drug Administration. WEGOVY® (semaglutide) prescribing information. 2026.
11. U.S. Food and Drug Administration. ZEPBOUND® (tirzepatide) prescribing information. 2026.

Bottom line: Tirzepatide produces more weight loss on average; semaglutide has a longer safety track record and gentler titration. Both work. The right choice depends on your goals, tolerance, and budget. A Pallas provider can help you decide — it takes about 2 minutes to start the intake.